Cancer Research

Article	Citations
Abstract P3-05-01: Role of TRIM24 in metaplastic breast cancer and nomination of potential therapeutic targets	326
Abstract P2-13-10: First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study	168
Abstract P1-08-05: Expression of the human APOE4 genotype modulates Doxorubicin cardiotoxicity in mice	159
Abstract P3-20-10: Local recurrences after mammary adenectomy with clear retroareolar margin for the treatment of early infiltrating breast carcinomas	150
Abstract P4-06-06: Role of lymphatic SEC62 expression in prediction of treatment response in patients undergoing neoadjuvant chemotherapy for primary breast cancer	150
Abstract PD1-09: Constitutively active estrogen receptor mutants enhance breast cancer pathogenesis by co-opting progesterone receptor activity, which can be countered by Giredestrant	146
Abstract ES5-3: Management of special subtypes of TNBC	137
Abstract P3-16-04: Estimation of willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A): The main study findings	132
Abstract P1-24-01: Does modified radical mastectomy in de novo stage IV inflammatory breast cancer patients improve disease specific survival?	131
Abstract PD3-05: The paradoxical role of RalA and RalB in triple negative breast cancer	126
Abstract P5-14-02: Breast cancer clinical trial participation rate among patients of low socioeconomic status at a comprehensive cancer center	123
Abstract P4-10-16: Increased chemotherapy-induced ovarian reserve loss and impaired oocyte quality in a mouse ATM knock-down model: An augury for women with ATM-pathway-pathogenic-variants-associated	119
Abstract P3-09-12: Breast cancer derived GATA3 mutations disrupt luminal transcriptional network	119
Abstract P1-21-05: GM-CSF is an autocrine driver of HER2+ breast leptomeningeal carcinomatosis	117
Abstract 588: Mesenchymal markers: The new avenue for circulating tumor cells detection	116
Abstract 3175: FAT1 and the immunosuppressive milieu in glioblastoma tumors	114
Abstract P1-13-04: Evaluation of the impact Vitamin D and Calcium supplementation on bone mineral density in breast cancer patients using or not taking Aromatase Inhibitors: 5-year follow-up	112
Abstract P4-02-16: Investigating the role of NRIP1 as a novel marker and therapeutic target for breast cancer	107
Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with	106
Abstract P4-04-03: Modulation of antitumor immunity by extracellular matrix environment in vitro	102
Abstract P2-14-14: Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2 negative stage II-III breast cancer	100
Abstract P2-11-18: Weekly evaluation of α estrogen and progesterone receptors in women´s breast epithelium after oral combined hormonal contraceptive use for one month	98
Abstract P4-12-03: Assessment of quality of life (QoL) in patients with metastatic breast cancer (MBC) in clinical practice: A real-world multi-country survey	98
Abstract P5-16-13: Safety and efficacy of INT230-6, a potential first-in-class intratumoral therapy, in monotherapy and in combination with pembrolizumab: Results from the IT-01 study [KEYNOTE-A10] in	98
Abstract P5-14-12: Health literacy among long term breast cancer survivors; exploring associated factors in a nation-wide sample	98

Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry	97
Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline BRCA pathogenic variants having a pregnancy after breast cancer	92
Abstract OT1-05-01: Glycoprotein 88 (GP-88) serum levels as a marker of response to therapy in patients with metastatic breast cancer	92
Abstract P1-02-15: Predicting molecular subtypes of breast cancer using	92
Abstract 1393: PSMA-Targeted Thorium Conjugate (BAY 2315497) and olaparib combination show synergistic anti-tumor activity in prostate cancer models	91
Abstract P3-08-02: The frequency and somatic mutation landscape of Fibroblast growth factor receptor (FGFR) alterations in breast cancer	89
Abstract P5-13-23: Pharmacokinetic determinants of palbociclib hematological toxicity	87
Abstract PD3-08: Novel cancer stem cell inhibitor 108600 modulates tumor immunomicroenvironment of triple negative breast cancer (TNBC)	87
Abstract 2126: Therapeutic potential of CPI-0209	86
Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy	85
Abstract P5-06-11: Secreted frizzled related protein 1: From lobular involution to breast osteoimmunological disorder	84
Abstract 111: Accurate multi-cancer detection using methylated DNA markers and proteins in plasma	84
Abstract P2-13-26: Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer (BC): First real-life data from the cohort temporary authorization for use (cATU)	82
Abstract P5-13-32: Mucin 4 expression in high risk breast cancer: Predicting and overcoming resistance to immunotherapy	77
Abstract 1199: Mosaic KRAS G12S mutation associates with poor outcome in papillary thyroid carcinoma: A case report	77
Abstract 1254: Preclinical studies with TGN-1062, a selective and reversible small molecule inhibitor of CDK7	77
Abstract P2-07-11: Application of the genetic signature MammaPrint™ in the Brazilian population - Real-world study (AGEMA-BRA)	76
Abstract P2-11-13: Distinctive clinicopathological features of premenopausal women with intermediate 21-gene recurrence score	75
Abstract P3-12-23: Characterization of triple-negative breast cancer in two Central American countries	75
Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC)	75
Abstract P4-11-09: Cancer-related cognitive impairment (CRCI) in early breast cancer (BC) survivors	75
Abstract 228: A precision dosing application for patients treated with docetaxel and G-CSF	74
Transcription Factor Fingerprint Provides Clues for Brain Tumor Cell of Origin	74
Editor’s Note: Mitochondrially Targeted p53 Has Tumor Suppressor Activities In vivo	73
Retraction: Loss of Metallothionein Predisposes Mice to Diethylnitrosamine-Induced Hepatocarcinogenesis by Activating NF-κB Target Genes	73
Mutant KRAS and CK2 Cooperatively Stimulate SLC16A3 Activity to Drive Intrahepatic Cholangiocarcinoma Progression	73
Retraction: A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation	71
Abstract PD14-05: Portraying tumor evolution of lobular breast cancer through phylogenetic analysis	67
Retraction: ANGPTL1 Interacts with Integrin α1β1 to Suppress HCC Angiogenesis and Metastasis by Inhibiting JAK2/STAT3 Signaling	67
Correction: Targeting KDM6A Suppresses SREBP1c-Dependent Lipid Metabolism and Prostate Tumorigenesis	67
Abstract P5-14-07: Financial toxicity in BRCA1 and BRCA2 carriers: A pilot study	66
Abstract P3-20-05: Trends of axillary treatment in sentinel node-positive breast cancer patients undergoing amputation	66
Abstract P1-02-16: Prediction of breast ductal carcinoma in situ recurrence using histomics analysis of stromal collagen from second-harmonic generation and hematoxylin and eosin stain-based images	65
Abstract P1-04-13: Generation and validation of an estrogen receptor signaling (ERS) gene panel that inversely correlates with antigen presentation and T cell infiltration and activity in hormone rece	65
Abstract P1-05-09: Analysis of immunophenotyping of patient-derived primary breast cancer cells according to the medium composition and culture method	65
Abstract P3-09-11: Clinical characteristics associated withBRCA1/2mutations identified on routine tumor tissue genotyping in metastatic breast cancer	65
Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer	65
Abstract 1082: Regorafenib resistance is associated with senescence-like phenotype and EMT in colorectal cancer (CRC)	64
Abstract P2-13-42: Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial	64
Abstract 1847: Anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP+ regulatory T cells	63
Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, H	62
Abstract P3-18-17: Impact of change in margin negative guidelines for breast cancer on recurrence rates: Single institution audit	61
SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA Suppression	61
Abstract P3-20-09: Surgery vs radiation therapy as the first stage treatment in patients with locally advanced breast cancer with incomplete clinical response	60
Abstract P3-12-20: Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer	60
Abstract P5-08-02: MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC	60
Abstract P1-04-01: Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC)	60
Abstract P5-05-10: Inhibition of FASN as a potential treatment of advanced therapy-resistant breast cancer	60
Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer	59
Abstract OT2-27-02: A prospective phase II study on efficacy and safety of anlotinib combined with fulvestrant in patients with HR-positive and HER2-negative, secondary endocrine-resistant, locally ad	58

Abstract P5-06-04: A multi-omics approach to study the host-microbiota interaction in breast cancer tissue	58
Abstract P3-03-21: Contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: Whart do they mean?	58
Abstract P4-07-10: Patient profiles, management and treatment patterns in HR+, HER2- early breast cancer in a real-world setting in Spain	58
Abstract P3-18-13: A cross-sectional study to investigate association between oncoplastic techniques and patient satisfaction who received breast-conserving surgery	57
Abstract PD7-07: Surgical management and contralateral breast cancer risk in women with a history of radiation therapy for Hodgkin lymphoma: Results from a population-based cohort	57
Abstract P2-09-17: Family communication and attitude of patients with breast cancer toward positive pathogenic BRCA1 or BRCA2 mutations. A regional perspective	56
Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis	55
Abstract 755: Lipid metabolites and the risk of pancreatic cancer in two nested case-control studies	55
Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T Cell Immunotherapy	54
Abstract LB071: Tuning the tumor myeloid microenvironment (TME) by targeting TREM2+ tumor-associated macrophages to overcome resistance to immune checkpoint inhibitors	53
Abstract 72: Bifidobacterium longum RAPO enhances efficacy of anti-PD-1 immunotherapy in a mouse model of triple-negative breast cancer	53
Abstract P5-13-13: PIK3CA mutations co-occurring with copy number gain identify patients with adverse outcome and potentially different treatment sensitivity among hormone receptor positive and	53
Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer	53
Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation	52
Abstract 1584: Efficacy and pharmacodynamic effect of anti-CD73/PD-L1 monoclonal antibodies in combination with chemotherapy: Observations from mouse tumor models	52
Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-	52
Highlights from Recent Cancer Literature	52
Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma	52
Abstract 336: Gut microbiome predicts response to CDK4/6 inhibitor and immune check point inhibitor combination in patients with hormone receptor positive metastatic breast cancer	51
ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation	51
ACSL4-Mediated Membrane Phospholipid Remodeling Induces Integrin β1 Activation to Facilitate Triple-Negative Breast Cancer Metastasis	50
Serine Depletion Promotes Antitumor Immunity by Activating Mitochondrial DNA-Mediated cGAS-STING Signaling	50
Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer	49
Neuroblastoma Differentiation: The Untapped Potential of Mitochondrial Uncouplers	49
A Histone Methylation–MAPK Signaling Axis Drives Durable Epithelial–Mesenchymal Transition in Hypoxic Pancreatic Cancer	49
Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway	49
Abstract LB015: Clinical evaluation of The Paris System-based artificial intelligence algorithm for reporting urinary cytopathology	49
CD24-Targeted NIR-II Fluorescence Imaging Enables Early Detection of Colorectal Neoplasia	49
Abstract P5-14-10: Examining inequities associated with incarceration among patients with breast cancer	48
Abstract 297: Innovation in delivering synthetically challenging bicyclic arginase inhibitors to enhance immunotherapy	48
Abstract 1018: SEL120, a CDK8/CDK19 inhibitor, possesses strong multilineage differentiation potential in AML	48
Abstract NG14: Reduction in mitochondrial priming drives resistance to targeted therapy in acute myeloid leukemia	48
Abstract P4-10-10: Effectiveness and feasibility of exercise-oncology programs in breast cancer patients using new technologies adapted to the COVID 19 new normality	48
Highlights from Recent Cancer Literature	48
Abstract P5-02-03: Phenotypic analysis for TNBC using a novel breast cancer microphysiological system	47
Abstract PD3-10: Dual epigenetic/autophagy inhibition as a novel strategy to tackle triple negative breast cancer	47
Abstract P3-05-07: The response of histone deacetylase inhibitors in triple negative breast cancer	47
Abstract P1-10-05: Evidence that body mass index modifies breast tissue collagen peptide response pattern to treatment with the non-steroidal anti-inflammatory drug sulindac	47
Abstract P4-11-28: Collecting quality of life information in a cohort of breast cancer survivors- Integrating electronic data collection into clinical practice	47
Abstract P2-08-03: PD-L1 protein expression in relation to Recurrence Score values in early stage ER+HER2- breast cancer	47
Abstract P4-07-09: Triple negative breast cancer: An analysis of the subtypes and the effects of menopausal status on invasive breast cancer	47
Abstract P1-02-08: Comparison of clinical features and outcomes for pleomorphic invasive lobular carcinoma vs. non-pleomorphic invasive lobular carcinoma	47
Abstract P1-07-08: Endoxifen predicts early recurrence in breast cancer: A Brazilian prospective study	46
Abstract P2-07-10: Germline BRCA screening for locally advanced breast cancer treated by neoadjuvant chemotherapy: Defining a subgroup with high rate of mutation and local relapses	46
Abstract ES8-2: Can radiation replace ALND after positive SLNB?	45
Abstract P1-21-03: Efficacy of tyrosine kinase inhibitors (TKI) in the treatment of patients with HER2-positive (HER2+) breast cancer with or without brain metastases: A systematic review and meta-ana	45
Abstract P2-13-38: Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia	45
Abstract P4-12-14: Assessing patients perceptions on hormone therapy for breast cancer: Insights from a Brazilian patient group	45
Abstract P4-01-15: Eribulin treatment for hormone receptor positive breast cancer cells with resistant to endocrine therapy promotes re-expression of estrogen receptor	45
Abstract P2-13-02: Pathologic nodal staging and systemic therapy among patients with cT1-2N0 HER2+ breast cancer: A prospective single institution cohort analysis	44
Abstract 296: Structure-based and property-based drug design of AZD5305, a highly selective PARP1 inhibitor and trapper	44
Abstract 328: Selective fluorogenic probe for rapid detection of cathepsin L activity	44
Highlights from Recent Cancer Literature	44
Abstract P1-01-16: Perspectives on axillary management after primary systemic treatment: An international EUBREAST survey	43
Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS	43
Abstract 3041: ASPSCR1-TFE3 gene fusion in transgenic mouse as a new pediatric kidney cancer model	43
Abstract OT1-15-01: SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: HER2-mutated breast cancer cohort (ongoing clinical t	43
Abstract LB051: The landscape of peptide vaccinein clinical trials for cancer	43
Abstract P2-01-15: Developing highly sensitive high NGS data efficient ctDNA detection assays for breast cancer surveillance	43
Abstract P2-12-23: Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer	43
Abstract P2-01-02: A whole blood assay to identify breast cancer: Interim analysis of the international identify breast cancer (IDBC) study evidence supporting the Syantra DX breast cancer test	43
Abstract P2-14-07: Marrow-infiltrating lymphocytes as adoptive immunotherapy for breast cancer	42
Abstract P2-06-03: Obesity is associated with DNA damage in the breast epithelium of BRCA1 and BRCA2 mutation carriers: A role for estrogens & strategies for prevention	42
Abstract P5-10-06: Arginine- depleting enzyme, pegylated arginase, isolated from beef-liver tissue induces growth inhibition, apoptosis, cell cycle arrest and inhibits induced mammary tumors: A promis	42
Abstract P4-04-11: Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients	42
Abstract P3-18-14: Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer	42
Abstract P3-19-16: Impact of targeted intraoperative (TARGIT-IORT) tumor bed boost during breast conserving surgery for early breast cancer on breast cancer associated and non-breast cancer associated	42
Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines	41
Abstract P3-12-31: A 10 year retrospective study of male breast cancer patients within central Scotland	40
Abstract P5-10-05: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers	40
Abstract P5-01-12: Physical and visual (social) isolation increases tumor aggressiveness in thermoneutral housing temperatures in murine mammary cancer models	40
Abstract P5-08-17: Small G protein RALA is a driver and potential therapeutic target in triple negative breast cancer	40
Abstract 1469: TPX-0131, a potent inhibitor of wild type ALK and a broad spectrum of both single and compound ALK resistance mutations	39
Abstract P3-11-01: Oncolytic herpes simplex virus immunovirotherapy eradicates breast cancer and prevents tumor relapse	39
Abstract 63: Chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models	39
Abstract 1384: Selective PI3Kγ inhibitor ZX-4081 reprograms the tumor microenvironment to facilitate anti-cancer immunity	39
Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC)	39
Abstract 1107: Precision phosphoproteomic analysis in Chr22q11.2 amplified NSCLC cells reveals distinct signaling corruption and response to Aurora kinase B inhibition	39
Abstract OT2-17-01: Randomized, multicenter, international phase 3 ARTEST study to evaluate the efficacy and safety of enobosarm versus active control for the treatment of AR+ ER+ HER2- metastatic bre	38
Abstract CT036: Axicabtagene ciloleucel (axi-cel) product attributes and immune biomarkers associated with clinical outcomes in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymph	38

Abstract P1-05-04: Novel breast cancer proteomic subtyping with connection to cell of origin	38
Abstract P1-08-29: The influence of pre-treatment peripheral blood inflammatory markers on post-treatment response in patients with locally advanced breast cancer (LABC) from Saudi Arabia	38
Abstract LB150: Clinical Feasibility and Treatment Outcomes with Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients with Advanced Cutaneous Melanoma	38
Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC)	38
Abstract P5-18-11: Impact of supportive therapies on tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer	38
Abstract 1717: MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models	38
Abstract CT123: Population pharmacokinetics of ripretinib in patients with advanced malignancies	38
Abstract P2-13-24: Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer	38
Abstract P5-12-11: NSDHL knockdown decreases tightly cohesive tumorsphere formation and breast cancer stem cell population	38
Ribosomal RNA Biosynthesis Functionally Programs Tumor-Associated Macrophages to Support Breast Cancer Progression	37
Abstract P5-11-03: Altered adipose-derived mesenchymal stem/stromal cells induced by obesity in the breast cancer microenvironment	37
Abstract 2449: FGFR4 inhibitor BLU9931 induces cellular senescence in pancreatic ductal adenocarcinoma cell lines promoting sensitivity to senolytic therapy	37
Retraction: mda-9/Syntenin Regulates the Metastatic Phenotype in Human Melanoma Cells by Activating Nuclear Factor-κB	37
Abstract P5-18-08: The relative risk of various endocrinopathies associated with neoadjuvant chemoimmunotherapy use in early-stage triple-negative breast cancer: A systematic review and meta-analysis	37
Abstract 2896: Effects of hypoxia on normal prostate fibroblast and prostate cancer associated fibroblast metabolism and matrix degradation	37
Comparison of Lean, Obese, and Weight Loss Models Reveals TREM2 Deficiency Attenuates Breast Cancer Growth Uniquely in Lean Mice and Alters Clonal T Cell Populations	37
Abstract 2889: γ-Tocotrienol inhibition of metastatic phenotypic behavior is associated with a decrease in galectin-3 expression and distribution in the highly malignant mouse +SA & TS/A mammary t	37
Abstract LB129: Stratification of radiotherapy and fluoropyrimidine-based chemotherapy from multi-omic profiling in rectal cancer biopsies	37
Abstract P1-08-34: Peripheral immunity predicts therapeutic outcomes in breast cancer patients	36
Abstract P3-14-07: Breast cancer screening disparities among insured women in the Washington DC-Baltimore area	36
Abstract PD7-08: Less is not necessarily more: A propensity matched national analysis on effect and outcome of sentinel lymph node biopsy omission	36
Abstract P5-12-03: Wcrc-25: A novel luminal invasive lobular carcinoma cell line model	36
Abstract 2977: Organoid-T-cell co-cultures for preclinical testing of adoptive cell and cancer immunotherapy	36
Abstract P3-09-03: Single nucletotide polymorphisms of aromatase gene (CYP19A1) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study	36
Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer	35
Abstract P3-09-18: The association between genomic alterations and body mass index in patients with early breast cancer	35
Abstract P4-07-20: Survival analysis using the entire transcriptome to pinpoint biomarkers with the highest prognostic power	35
Abstract P5-12-07: Proteomic profiling of extracellular vesicles released from leptin-treated breast cancer cells: A potential role in cancer metabolism	35
Abstract P1-01-01: Prospective ultrasonographic surveillance study for incidence and recovery period of COVID-19 vaccination-related axillary lymphadenopathy	35
Abstract GS2-09: Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations	35
Abstract PD9-05: Prognostic and tamoxifen-predictive effect of PAM50 and ROR score in premenopausal women included in the randomised SBII:2 trial	35
Abstract CT144: Development of GMI-1359, a novel agent targeting tumor-microenvironment cross-talk in bone metastatic cancer	35
Abstract P2-12-04: Characterization of gut microbiome composition in triple negative breast cancer patients treated with neoadjuvant chemotherapy	34
Abstract P3-23-07: Radiation induced angiosarcoma of the breast: Chemotherapy for radiation induced angiosarcoma of the breast - An individual participant data meta-analysis of Japanese population	34
Abstract P4-07-30: Residual lymphovascular invasion: Predicts the outcome of neoadjuvant chemotherapy in locally advanced breast cancer	34
Abstract P4-01-17: Preventing adaptive therapeutic resistance to CDK4/6 inhibition with CDK8/19 inhibitors	34
Abstract P1-17-05: Benefit of endocrine therapy for metastatic breast cancer after loss of hormone receptor expression in patients with HR+/HER2- primary tumors	33
Abstract P3-12-36: The diagnosis and prognosis of ductal carcinoma in situ (DCIS) with microinvasion - Results from the United Kingdom Sloane project	33
Abstract P1-08-27: Dynamic monitoring of circulating tumor DNA can predict chemotherapy response and prognosis in metastatic triple-negative breast cancer patients	33
Abstract P5-13-17: PD-L1 expression in breast to brain metastases	33
Abstract 286: Conception and preparation of new potent antimicrotubule agents	33
Abstract P2-10-09: Oxysterol profiling in breast adipose tissue identifies brassicasterol and 24-hydroxycholesterol as breast cancer risk predictors	33
Abstract P4-05-04: Menopausal breast cancer: Bone mineral density (BMD) and prognostic factors	33
Abstract 715: Flow cytometry analysis of immune response to COVID-19 vaccine candidates using an in vitro stimulation model	33
Abstract P5-16-08: Phase Ib/II trial evaluating safety and efficacy of copanlisib (PI3K inhibitor) and trastuzumab in pre-treated advanced HER2-positive breast cancer: Results from the PantHER study	33
Abstract P1-01-09: Prediction of node negative breast cancer and high disease burden through image analysis software on mammographic images and clinicopathological data	32
Abstract P2-12-13: Pathologic complete response rate according to the carboplatin dose in patients with non-metastatic HER2+ breast cancer treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pe	32
Abstract PD3-03: EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression	32
Abstract 3049: Tumor treating fields induce DNA damage and apoptosis in medulloblastoma	32
Abstract OT2-21-01: A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adj	32
Abstract P3-04-02: Real world evidence demonstrates replacement of 2D mammography with 3D mammography among insured women	32
Abstract LB044: Tracking clonal hematopoiesis in patients with classical Hodgkin lymphoma	32
Abstract 1220: Selective and broad anti-tumor activity of AKR1C3-activated prodrug AST-3424/OBI-3424	32
Abstract OT1-09-01: A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In S<	32
Abstract 1472: Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical need	31
Abstract P1-17-08: Abemaciclib and endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: A real-world UK multicentre experience	31
Abstract P5-14-06: Predictors of adherence to oral endocrine therapy in racial and ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic	31
Abstract P5-06-07: Selective inhibition of fibroblast-specific domain discoidin receptor 1 (DDR1) results in reduced collagen deposition and immunomodulatory cytokine release: A potential target to mo	31
Abstract P2-02-04: In early breast cancer, the ratios of neutrophils, monocyctes and platelets to lymphocytes significantly correlate with the presence of subsets of circulating tumor cells in blood a	31
Abstract OT1-04-02: The NAUTILUS trial (No Axillary sUrgical Treatment In clinically Lymph node negative patients after UltraSonography): A prospective multicenter randomized phase III trial (NCT04303	31
Abstract P5-16-18: Developing IpY: A novel inhibitor for the treatment of ER+ CDK4i-resistant breast cancer	31
Abstract P4-02-04: Endocrine therapy treatment radiosensitizes estrogen receptor-positive breast cancers	31
Abstract P4-11-05: How to stay sexually active and sexually well-functioning after breast cancer - Reporting from the SWEET study	31
Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience	31
Abstract CT203: First-in-human phase 1b study of ATRC-101, a patient-derived antibody with a tumor-specific target, as monotherapy or in combination with pembrolizumab, in patients with solid tumors	31
Abstract P3-13-01: Association of polygenic risk score with 2 year risk of poor prognosis breast cancer	31
Abstract P5-06-01: Spatiotemporal gene expression analysis to identify novel tumor-neural crosstalk in TNBC brain metastases	31
Abstract P3-19-07: Hypofractionated and conventional whole-breast radiotherapy for breast cancer patients: Financial risk and expenditures in the U.S. 2008-2017	30
Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma	30
Abstract 3164: Modeling the metastatic niche interactions between patient tumor and mesenchymal cells to identify drivers of chemotherapy drug resistance	30
Abstract 1928: Erdafitinib in combination with BCLXL/BCL2 inhibitor induce apoptosis in urothelial carcinoma cells without FGFR mutation	30
Abstract P5-02-05: Optimizing the differentiation of the 3T3-L1 MBX mouse cell line to mature and obese adipocytes for in vitro breast cancer studies	30
Abstract OT1-12-04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early	30
Abstract P1-19-01: Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone - A large institutional	30
Abstract P3-09-17: Systems-scale characterization of the human immunome in breast cancer for precision medicine	30
Abstract PD5-02: Cardioprotective strategy for non-metastatic breast cancer patients receiving an anthracycline-based chemotherapy: subgroup analysis focused on impact of postoperative breast radiatio	30
Abstract P5-12-06: Msc engulfing by triple negative breast cancer cells induces a hybrid cell population with senescence	30
Abstract 60: Induction of T cell dysfunction and NK-like T cell differentiation in vitro and in patients after CAR T cell treatment	29
Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated wi	29
Highlights from Recent Cancer Literature	29
Abstract 735: hPG80 (circulating progastrin), a novel blood-based biomarker for detection of poorly differentiated neuroendocrine carcinoma and well differentiated neuroendocrine tumors	29
Abstract 442: Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189	29
Abstract 1363: Exposure-toxicity analysis of cabozantinib in patients with salivary gland cancer and renal cell cancer	29
Abstract 1708: Improving genotype specific chemotherapy response in ovarian cancer via cGAS-STING pathway activation	29
Highlights from Recent Cancer Literature	29
Abstract PD10-09: Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment	29
Abstract P2-01-06: Detection of circulating tumor DNA post neoadjuvant chemotherapy using a personalized assay is associated with disease relapse	29
Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PAD	29
mTOR-Dependent ARID1A Degradation: A New Twist in the Genetic–Epigenetic Interplay Driving Hepatocellular Carcinoma	29
Abstract OT2-16-01: The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and	28
Abstract P1-06-01: Insights from rapid autopsy shed light on mechanisms of cancer dissemination in metastatic breast cancer	28
Abstract P4-05-08: 18F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence	28
Abstract ES3-2: Clinical management of moderate penetrance genes	28
Abstract P4-06-02: Clinically feasible pharmacokinetic model of dynamic contrast-enhanced MRI is prognostic of recurrence free survival in breast cancer patients treated with neoadjuvant therapy	28
Abstract P3-18-01: Assessmentof DCISionRT for guiding radiotherapy of DCIS in Sweden	28